The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 5 , Pages 1295-1305.e4 , May 2010

Bridge to transplant experience: Factors influencing survival to and after cardiac transplant

Presented at the 87th annual meeting of the American Association for Thoracic Surgery, May 5–9, 2007, Washington, DC.

  • Nicholas G. Smedira, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio
    • George M. and Linda H. Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio
    • Corresponding Author InformationAddress for reprints: Nicholas G. Smedira, MD, Surgical Director, Kaufman Center for Heart Failure, Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, 9500 Euclid Avenue/J4-1, Cleveland, OH 44195.
    • ,
  • Katherine J. Hoercher, RN

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio
    • George M. and Linda H. Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Dustin Y. Yoon, MS

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Jeevanantham Rajeswaran, MSc

      Affiliations

    • Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Lynne Klingman, MT, CHS

      Affiliations

    • Allogen Laboratories, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Randall C. Starling, MD, MPH

      Affiliations

    • George M. and Linda H. Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio
    • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Eugene H. Blackstone, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio
    • Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio

Received 3 May 2007 ,Revised 13 November 2009 ,Accepted 7 December 2009.

References 

  1. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Waltz DA, Keck BM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report—2006. J Heart Lung Transplant. 2006;25:869–879
  2. Gammie JS, Edwards LB, Griffith BP, Pierson RN, Tsao L. Optimal timing of cardiac transplantation after ventricular assist device implantation. J Thorac Cardiovasc Surg. 2004;127:1789–1799
  3. Kirklin JK, Naftel DC, Bourge RC, McGiffin DC, Hill JA, Rodeheffer RJ, et al. Evolving trends in risk profiles and causes of death after heart transplantation: a ten-year multi-institutional study. J Thorac Cardiovasc Surg. 2003;125:881–890
  4. Sun BC, Catanese KA, Spanier TB, Flannery MR, Gardocki MT, Marcus LS, et al. 100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience. Ann Thorac Surg. 1999;68:688–694
  5. Jaski BE, Kim JC, Naftel DC, Jarcho J, Costanzo MR, Eisen HJ, et al. Cardiac transplant outcome of patients supported on left ventricular assist device vs. intravenous inotropic therapy. J Heart Lung Transplant. 2001;20:449–456
  6. Kormos RL, Breen TJ, Frazier OH, Hosenpud JD. Sub-study analysis of ISHLT/UNOS Registry, Richmond, VA: use of ventricular assist devices before heart transplant effects of type of support on transplant survival. J Heart Lung Transplant. 1995;14:S67
  7. Betkowski AS, Graff R, Chen JJ, Hauptman PJ. Panel-reactive antibody screening practices prior to heart transplantation. J Heart Lung Transplant. 2002;21:644–650
  8. Kumpati GS, Cook DJ, Blackstone EH, Rajeswaran J, Abdo AS, Young JB, et al. HLA sensitization in ventricular assist device recipients: does type of device make a difference?. J Thorac Cardiovasc Surg. 2004;127:1800–1807
  9. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley; 1980;
  10. Blackstone EH, Naftel DC, Turner ME. The decomposition of time-varying hazard into phases, each incorporating a separate stream of concomitant information. J Am Stat Assoc. 1986;81:615–624
  11. Breiman L. Bagging predictors. Machine Learning. 1996;24:123–140
  12. Morgan JA, John R, Rao V, Weinberg AD, Lee BJ, Mazzeo PA, et al. Bridging to transplant with the HeartMate left ventricular assist device: The Columbia Presbyterian 12-year experience. J Thorac Cardiovasc Surg. 2004;127:1309–1316
  13. Miller LW, Lietz K. Candidate selection for long-term left ventricular assist device therapy for refractory heart failure. J Heart Lung Transplant. 2006;25:756–764
  14. Lietz K, Long J, Kfoury AG, Slaughter MS, Silver MA, Milano CA, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007;116:497–505
  15. Deng MC, Edwards LB, Hertz MI, Rowe AW, Keck BM, Kormos R, et al. Mechanical Circulatory Support Device Database of the International Society for Heart and Lung Transplantation: second annual report—2004. J Heart Lung Transplant. 2004;23:1027–1034
  16. John R, Pagani FD, Naka Y, Conte JV, Klodell CT, Milano CA, et al. Duration of LVAD support does not impact post-cardiac transplant survival in the continuous-flow pump era. Presented at the 89th Annual Meeting of the American Association for Thoracic Surgery, May 9-11, Boston, 2009.
  17. Fitzpatrick JR, Frederick JR, Hiesinger W, Hsu VM, McCormick RC, Kozin ED, et al. Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg. 2009;137:971–977
  18. Moazami N, Itescu S, Williams MR, Argenziano M, Weinberg A, Oz MC. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant. 1998;17:876–880
  19. Massad MG, Cook DJ, Schmitt SK, Smedira NG, McCarthy JF, Vargo RL, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg. 1997;64:1120–1125
  20. Itescu S, Tung TC, Burke EM, Weinberg A, Moazami N, Artrip JH, et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation. 1998;98:786–793
  21. Pagani FD, Dyke DB, Wright S, Cody R, Aaronson KD. Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival. J Heart Lung Transplant. 2001;20:646–653
  22. Joyce DL, Southard RE, Torre-Amione G, Noon GP, Land GA, Loebe M. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes. J Heart Lung Transplant. 2005;24:2054–2059
  23. Gupta S, Cook DJ, Sharma M, Stawinski G, Taylor D, Yamani MH, et al. Virtual crossmatching" allows the expansion of effective donor pool for HLA-sensitized patients. [abstract] J Heart Lung Transplant. 2006;25:S140
  24. Bishay ES, Cook DJ, Starling RC, Ratliff NB, White J, Blackstone EH, et al. The clinical significance of flow cytometry crossmatching in heart transplantation. Eur J Cardiothorac Surg. 2000;17:362–369
  25. Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54:312–321

 D.Y.Y. supported by the American Heart Association Pre-doctoral Fellowship. E.H.B. supported in part by the Kenneth Gee and Paula Shaw, PhD, Chair in Heart Research.

 Disclosures: None.

PII: S0022-5223(09)01600-6

doi: 10.1016/j.jtcvs.2009.12.006

The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 5 , Pages 1295-1305.e4 , May 2010

Article Tools

* Image Usage & Resolution